CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office has granted the previously allowed Tuschl II patent. The European patent (EP 1407044 or “ ’044 Patent”) broadly covers compositions, methods, and uses of small interfering RNAs (siRNAs), the molecules that mediate RNAi. In addition, the company announced today that the German Patent Office has granted a new patent (DE 10066235 or “ ’235 patent”) in the Kreutzer-Limmer I patent series broadly covering methods, uses, and medicaments for siRNAs with a length of 15 to 49 nucleotide pairs expressed via vectors.
